AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis
USA - NASDAQ:FOLD - US03152W1099 - Common Stock
9.19 USD
+0.2 (+2.22%)
9.4965 USD
+0.31 (+3.34%)
Taking everything into account, FOLD scores 4 out of 10 in our fundamental rating. FOLD was compared to 534 industry peers in the Biotechnology industry. FOLD has a medium profitability rating, but doesn't score so well on its financial health evaluation. FOLD is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year FOLD was profitable.
In the past year FOLD has reported a negative cash flow from operations.
In the past 5 years FOLD always reported negative net income.
FOLD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -4.67%, FOLD belongs to the top of the industry, outperforming 87.45% of the companies in the same industry.
FOLD's Return On Equity of -18.65% is amongst the best of the industry. FOLD outperforms 85.58% of its industry peers.
FOLD's Return On Invested Capital of 3.06% is amongst the best of the industry. FOLD outperforms 91.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.67% | ||
| ROE | -18.65% | ||
| ROIC | 3.06% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FOLD has a Operating Margin of 4.39%. This is amongst the best in the industry. FOLD outperforms 90.45% of its industry peers.
FOLD's Gross Margin of 90.37% is amongst the best of the industry. FOLD outperforms 91.76% of its industry peers.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.39% | ||
| PM (TTM) | N/A | ||
| GM | 90.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), FOLD is destroying value.
FOLD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FOLD has been increased compared to 5 years ago.
The debt/assets ratio for FOLD has been reduced compared to a year ago.
2.2 Solvency
FOLD has an Altman-Z score of -0.72. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
FOLD's Altman-Z score of -0.72 is in line compared to the rest of the industry. FOLD outperforms 56.93% of its industry peers.
A Debt/Equity ratio of 1.92 is on the high side and indicates that FOLD has dependencies on debt financing.
With a Debt to Equity ratio value of 1.92, FOLD is not doing good in the industry: 79.78% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.72 |
ROIC/WACC0.33
WACC9.39%
2.3 Liquidity
FOLD has a Current Ratio of 3.21. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD's Current ratio of 3.21 is on the low side compared to the rest of the industry. FOLD is outperformed by 62.17% of its industry peers.
FOLD has a Quick Ratio of 2.29. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD has a Quick ratio of 2.29. This is in the lower half of the industry: FOLD underperforms 69.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 2.29 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 123.53%, which is quite impressive.
FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.29%.
Measured over the past years, FOLD shows a very strong growth in Revenue. The Revenue has been growing by 23.73% on average per year.
EPS 1Y (TTM)123.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%950%
Revenue 1Y (TTM)32.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
3.2 Future
The Earnings Per Share is expected to grow by 70.90% on average over the next years. This is a very strong growth
Based on estimates for the next years, FOLD will show a very strong growth in Revenue. The Revenue will grow by 20.44% on average per year.
EPS Next Y73.29%
EPS Next 2Y89.17%
EPS Next 3Y71.81%
EPS Next 5Y70.9%
Revenue Next Year19.05%
Revenue Next 2Y20.13%
Revenue Next 3Y19.68%
Revenue Next 5Y20.44%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 114.87 indicates a quite expensive valuation of FOLD.
Based on the Price/Earnings ratio, FOLD is valued cheaply inside the industry as 90.45% of the companies are valued more expensively.
FOLD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.13.
FOLD is valuated quite expensively with a Price/Forward Earnings ratio of 32.34.
Based on the Price/Forward Earnings ratio, FOLD is valued cheaply inside the industry as 90.82% of the companies are valued more expensively.
FOLD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 114.87 | ||
| Fwd PE | 32.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, FOLD is valued cheaply inside the industry as 90.07% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 86.77 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 71.81% in the coming years.
PEG (NY)1.57
PEG (5Y)N/A
EPS Next 2Y89.17%
EPS Next 3Y71.81%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.19
+0.2 (+2.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.58%
Inst Owner Change-0.31%
Ins Owners0.6%
Ins Owner Change2.67%
Market Cap2.83B
Revenue(TTM)528.29M
Net Income(TTM)-38096000
Analysts84.71
Price Target16.32 (77.58%)
Short Float %6.4%
Short Ratio4.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.84%
Min EPS beat(2)-26.06%
Max EPS beat(2)41.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.25%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)7
Avg Revenue beat(12)-0.51%
Revenue beat(16)8
Avg Revenue beat(16)-1.25%
PT rev (1m)0.63%
PT rev (3m)2.13%
EPS NQ rev (1m)-0.46%
EPS NQ rev (3m)92.85%
EPS NY rev (1m)-5.2%
EPS NY rev (3m)41.41%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)0.85%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 114.87 | ||
| Fwd PE | 32.34 | ||
| P/S | 4.96 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 13.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 86.77 |
EPS(TTM)0.08
EY0.87%
EPS(NY)0.28
Fwd EY3.09%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.85
BVpS0.66
TBVpS-0.03
PEG (NY)1.57
PEG (5Y)N/A
Graham Number1.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.67% | ||
| ROE | -18.65% | ||
| ROCE | 3.87% | ||
| ROIC | 3.06% | ||
| ROICexc | 4.75% | ||
| ROICexgc | 9.73% | ||
| OM | 4.39% | ||
| PM (TTM) | N/A | ||
| GM | 90.37% | ||
| FCFM | N/A |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.88 | ||
| Cap/Depr | 41.25% | ||
| Cap/Sales | 0.57% | ||
| Interest Coverage | 0.44 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.21 | ||
| Quick Ratio | 2.29 | ||
| Altman-Z | -0.72 |
F-Score5
WACC9.39%
ROIC/WACC0.33
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%950%
EPS Next Y73.29%
EPS Next 2Y89.17%
EPS Next 3Y71.81%
EPS Next 5Y70.9%
Revenue 1Y (TTM)32.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
Revenue Next Year19.05%
Revenue Next 2Y20.13%
Revenue Next 3Y19.68%
Revenue Next 5Y20.44%
EBIT growth 1Y191.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.62%
EBIT Next 3Y105.52%
EBIT Next 5YN/A
FCF growth 1Y63.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.94%
OCF growth 3YN/A
OCF growth 5YN/A
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the fundamental rating for FOLD stock?
ChartMill assigns a fundamental rating of 4 / 10 to FOLD.
What is the valuation status of AMICUS THERAPEUTICS INC (FOLD) stock?
ChartMill assigns a valuation rating of 4 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.
What is the profitability of FOLD stock?
AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.
What are the PE and PB ratios of AMICUS THERAPEUTICS INC (FOLD) stock?
The Price/Earnings (PE) ratio for AMICUS THERAPEUTICS INC (FOLD) is 114.87 and the Price/Book (PB) ratio is 13.87.
Can you provide the financial health for FOLD stock?
The financial health rating of AMICUS THERAPEUTICS INC (FOLD) is 3 / 10.